Stockreport

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 [Yahoo! Finance]

Prelude Therapeutics Incorporated  (PRLD) 
PDF Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 clinical trial in second half of 2024 Recently established par [Read more]